187 related articles for article (PubMed ID: 30311656)
1. CHL1 expression differentiates Hürthle cell carcinoma from benign Hürthle cell nodules.
Li W; Xia S; Aronova A; Min IM; Verma A; Scognamiglio T; Gray KD; Ullmann TM; Liang H; Moore MD; Elemento O; Zarnegar R; Fahey TJ
J Surg Oncol; 2018 Nov; 118(6):1042-1049. PubMed ID: 30311656
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Subcellular Localization of Protein Biomarkers Distinguishes Benign from Malignant Thyroid Nodules: Potential for Fine-Needle Aspiration Biopsy Clinical Application.
Ralhan R; Veyhl J; Chaker S; Assi J; Alyass A; Jeganathan A; Somasundaram RT; MacMillan C; Freeman J; Vescan AD; Witterick IJ; Walfish PG
Thyroid; 2015 Nov; 25(11):1224-34. PubMed ID: 26131603
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration.
Agretti P; Ferrarini E; Rago T; Candelieri A; De Marco G; Dimida A; Niccolai F; Molinaro A; Di Coscio G; Pinchera A; Vitti P; Tonacchera M
Eur J Endocrinol; 2012 Sep; 167(3):393-400. PubMed ID: 22728346
[TBL] [Abstract][Full Text] [Related]
4. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
5. Molecular alterations in Hürthle cell nodules and preoperative cancer risk.
Doerfler WR; Nikitski AV; Morariu EM; Ohori NP; Chiosea SI; Landau MS; Nikiforova MN; Nikiforov YE; Yip L; Manroa P
Endocr Relat Cancer; 2021 Apr; 28(5):301-309. PubMed ID: 33792557
[TBL] [Abstract][Full Text] [Related]
6. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.
Sodré AK; Rubio IG; Galrão AL; Knobel M; Tomimori EK; Alves VA; Kanamura CT; Buchpiguel CA; Watanabe T; Friguglietti CU; Kulcsar MA; Medeiros-Neto G; Camargo RY
J Clin Endocrinol Metab; 2008 Oct; 93(10):4141-5. PubMed ID: 18628528
[TBL] [Abstract][Full Text] [Related]
7. PVALB, a new Hürthle adenoma diagnostic marker identified through gene expression.
Cerutti JM; Oler G; Delcelo R; Gerardt R; Michaluart P; de Souza SJ; Galante PA; Huang P; Riggins GJ
J Clin Endocrinol Metab; 2011 Jan; 96(1):E151-60. PubMed ID: 20926528
[TBL] [Abstract][Full Text] [Related]
8. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
9. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
Elliott DD; Pitman MB; Bloom L; Faquin WC
Cancer; 2006 Apr; 108(2):102-9. PubMed ID: 16453320
[TBL] [Abstract][Full Text] [Related]
10. Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.
Borrelli N; Ugolini C; Giannini R; Antonelli A; Giordano M; Sensi E; Torregrossa L; Fallahi P; Miccoli P; Basolo F
Cancer Cytopathol; 2016 May; 124(5):340-9. PubMed ID: 26749005
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylated Mechanistic Target of Rapamycin (p-mTOR) and Noncoding RNA Expression in Follicular and Hürthle Cell Thyroid Neoplasm.
Covach A; Patel S; Hardin H; Lloyd RV
Endocr Pathol; 2017 Sep; 28(3):207-212. PubMed ID: 28660408
[TBL] [Abstract][Full Text] [Related]
12. Report of a hürthle cell neoplasm in a peripubertal girl.
Bremer AA; Feldman BJ; Iezza G; Clark OH; Rosenthal SM
Thyroid; 2007 Feb; 17(2):175-8. PubMed ID: 17316121
[TBL] [Abstract][Full Text] [Related]
13. Impact of specific patterns on the sensitivity for follicular and Hurthle cell carcinoma in thyroid fine-needle aspiration.
Renshaw AA; Gould EW
Cancer Cytopathol; 2016 Oct; 124(10):729-736. PubMed ID: 27322887
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer.
Vriens MR; Weng J; Suh I; Huynh N; Guerrero MA; Shen WT; Duh QY; Clark OH; Kebebew E
Cancer; 2012 Jul; 118(13):3426-32. PubMed ID: 22006248
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.
Finley DJ; Arora N; Zhu B; Gallagher L; Fahey TJ
J Clin Endocrinol Metab; 2004 Jul; 89(7):3214-23. PubMed ID: 15240595
[TBL] [Abstract][Full Text] [Related]
16. Sonographically suspicious thyroid nodules with initially benign cytologic results: the role of a core needle biopsy.
Ha EJ; Baek JH; Lee JH; Song DE; Kim JK; Shong YK; Hong SJ
Thyroid; 2013 Jun; 23(6):703-8. PubMed ID: 23544697
[TBL] [Abstract][Full Text] [Related]
17. CITED1 protein expression suggests Papillary Thyroid Carcinoma in high throughput tissue microarray-based study.
Prasad ML; Pellegata NS; Kloos RT; Barbacioru C; Huang Y; de la Chapelle A
Thyroid; 2004 Mar; 14(3):169-75. PubMed ID: 15072698
[TBL] [Abstract][Full Text] [Related]
18. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
19. A panel of four genes accurately differentiates benign from malignant thyroid nodules.
Wang QX; Chen ED; Cai YF; Li Q; Jin YX; Jin WX; Wang YH; Zheng ZC; Xue L; Wang OC; Zhang XH
J Exp Clin Cancer Res; 2016 Oct; 35(1):169. PubMed ID: 27793213
[TBL] [Abstract][Full Text] [Related]
20. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm.
Sorrenti S; Trimboli P; Catania A; Ulisse S; De Antoni E; D'Armiento M
Thyroid; 2009 Apr; 19(4):355-60. PubMed ID: 19355826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
